

HOW DOES UNDERLYING CARDIOPULMONARY DISEASE INFLUENCE RESPONSE TO PM IN ANIMALS?

Urmila P. Kodavanti

U.S. Environmental Protection Agency, Office of Research and Development, NHEERL/ETD/PTB

research
and
development

Introduction

- “The moral test of a government is how it treats those who are at the dawn of life, the children; Those who are in the twilight of life, the aged; And those who are in the shadow of life, The sick, the needy and the handicapped.” (Hubert Humphrey, 1976)
- Epidemiological studies show that PM exposure increases mortality and morbidity, especially in elderly with cardiovascular and pulmonary diseases. However, these studies can provide only associations, and clinical studies are limited with ethical concerns, especially in frail individuals.
- Careful use of animal models with naturally occurring genetic predisposition, experimentally created genetic manipulations, and chemically or surgically induced diseases allow one to identify mechanisms and risk factors which predispose humans exacerbated injuries.


Research Goals

- Identify/develop animals models of human cardiovascular and chronic pulmonary diseases, and conduct PM studies in parallel to healthy models. Determine if susceptibility can be linked to humans, based on common biomarker evaluations.
- Investigate the roles of physiological and genetic factors, using genetic and experimentally created animal models. Investigate the role of common susceptibility factors, such as underlying oxidative stress.
- Investigate mechanisms of PM component-specific exacerbation of disease conditions. Identify the role of neurohumoral, and systemic factors in acute versus chronic PM health effects.
- Determine susceptibility in relation to disease progression. Develop integrated approaches which allow the use animal data to support human susceptibility.

Genetic and environmental interactions

Genetic Make-Up
-Monogenic/polygenic
-Disease sensitivity
-Species/strain
-Gender

Environmental
-Exposures
-Infections
-Personal Habits
-Nutrition



Methods/Approach

Animal Models

Cardiovascular Diseases Models

Spontaneously Hypertensive (SH) rats- genetic

Experimental MI

Apo E-/-

Pulmonary Disease Models

Asthma, Ova mice

ARDS-pulmonary vasculitis-MCT

Experimental COPD/bronchitis

Infections


PM Sources

Oil combustion-derived fugitive emissions, diesel, ambient collected, individual components, real time concentrated ambient PM, synthetic ultrafines

Health Outcomes


Cardiac and pulmonary physiology, systemic biomarkers, hematological and coagulation markers, vascular physiology, conventional and high-throughput gene and protein expressions, inflammation and oxidative stress markers, pathology

Underlying diseases affect particle deposition dose




Spontaneously Hypertensive (SH) Rat as a Model of Genetic Cardiovascular Disease


TOL-4 signaling demonstrate an active state in lungs of SH than in WKY rats; with PM exerting additional exacerbation



Greater oxidative stress in SH than in WKY rats following acute PM exposure




Fibrinogen increase in SH but not in WKY rats following inhalation of PM





Experimental Myocardial Infarction: A Rat Model

ST segment elevation in CAPs exposed rats immediately following surgical MI




Pulmonary Vasculitis Model

Although with high concentrations of particles, underlying pulmonary vasculitis was associated with exacerbated cardiac impairments and pulmonary pathology




Mouse Model of Atherosclerosis (ApoE-/-)

Increased vascular lesions in ApoE-/- but not wild-type mice




Rat Model of Sulfur Dioxide-Induced Bronchitis

Bronchitic rats demonstrate increased sensitivity to concentrated PM (CAPs)-induced inflammation




Chronic Obstructive Pulmonary Disease (COPD): Rat Models

Genetic differences determine variations in susceptibility to experimental COPD or PM-induced pulmonary impairments




Mouse Model of Allergic Asthma: Ovalbimin


Rats exposed to residual oil fly ash increases airway reactivity during allergic sensitization to house dust mite allergen



Thiol antioxidants inhibit adjuvant effect of inhaled DEP



Toxicological Paradigm for Use of Susceptible Disease Models



Future Directions

- Continue investigating mechanisms of underlying diseases in exacerbation of component-specific PM effects on pulmonary and cardiovascular systems.
- Delineate the roles of genetic versus physiological and environmental risk factors via use of transgenic, natural polygenic, and experimental models.
- Provide linkage between human and animal models Using high through put genomic/proteomic approaches.
- Investigate exacerbation due to acute versus long-term PM exposures focusing on host compensatory mechanisms.

The knowledge on genetic and environmental interactions in determining variations in susceptibility will improve our judgmental ability for determining risks of PM to most vulnerable populations.

Outcomes and Impact

To protect health of most susceptible individuals, we need to understand the mechanisms of variations in human susceptibilities. Epidemiological studies have demonstrated that PM exposure increases mortality and morbidity in individuals with cardiopulmonary diseases.

Our use of animal models demonstrate exacerbation of PM effects; and identify genetics, the existence of disease, and altered physiology as major risk factors. Although, more research is needed to identify specific genetic and epigenetic mechanisms.

Human susceptibility is an emerging biomedical field. The combination of genomic/proteomic approaches and animal models will provide mechanistic understanding of susceptibility.

The understanding of the genetic and environmental risk factors which predispose humans to increased susceptibility are essential in judging how much PM burden can be taken by those frail with increasing morbidity and mortality.

Health and Exposure